Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: A multicenter, phase II clinical trial

Journal of Thoracic Oncology

Volumn 2, Issue 10, 2007, Pages 933-938

  Weiss, Glen J ^a   Vokes, Everett E ^a   Bunn Jr , Paul A ^b   Magree, Lyn ^c   Rusk, Jason ^d   Albert, Don ^d   Kelly, Karen ^e,f  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d OSI PHARMACEUTICALS INC   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^f UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

Chemotherapy; Docetaxel; Exisulind; Non small cell lung cancer

Indexed keywords

DOCETAXEL; SULINDAC SULFONE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATAXIA; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DIZZINESS; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LACRIMATION; LEG PAIN; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MENTAL HEALTH; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; ONYCHOMYCOSIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION PNEUMONIA; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; SULINDAC; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 34848866295     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181462051     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
3. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation and attenuated β-catenin. Cancer Res 2000;60:3338-3342.
4. Witta SE, Gustafson DL, Pierson AS, et al. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clin Cancer Res 2004;10:7229-7237.
5. Han EK, Arber N, Yamamoto H, et al. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat 1998;48:195-203.
6. Richter M, Weiss M, Weinberger I, Furstenberger G, Marian B. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 2001;22:17-25.
7. Malkinson AM, Koski KM, Dwyer-Nield LD, et al. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumour formation by FGN-1 (sulindac sulfone). Carcinogenesis (Lond) 1998;19:1353-1356.
8. Thompson HJ, Jiang C, Lu J, et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 1997;57:167-171.
9. Goluboff ET, Shabsigh A, Saidi JA, et al. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 1999;53:440-445.
10. Chan DC, Earle KA, Zhao TL, et al. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res 2002;8:904-912.
11. Whitehead CM, Earle KA, Fetter J, et al. Exisulind-induced apotosis in a non-small cell lung cancer orthotopic lung tumor model auments docetaxel treatment and contributes to increased survival. Mol Cancer Ther 2003;2:479-488.
12. van Stolk R, Stoner G, Hayton WL, et al. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 2000;6:78-89.
13. Goluboff ET, Prager D, Rukstalis D, et al. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J Urol 2001;166:882-886.
14. Kelly K, Mikhaeel N, Dempsey J, et al. A phase I study of exisulind in previously treated patients with lung cancer. Lung Cancer 2000;29:76.
15. Jones SF, Kuhn JG, Raefsky EL, et al. A phase I study of exisulind in combination with docetaxel/carboplatin in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002;21:329a.
16. Lilenbaum RC, Schwartz MA, Seigel L, et al. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer 2001;92:2158-2163.
17. Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996;88:2801-2806.
18. Arbuck SG, Ivy SP, Setser A, et al. The Revised Common Toxicity Criteria: Version 2.0. Available at: http://ctep.info.nih.gov. Accessed July 12, 2007.
19. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 2000;18:3558-3585.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
21. Fleming TR. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-151.
22. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958;53:457-481.
23. Camps C, Massuti B, Jiménez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006;17:467-472.
24. Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004;91:1996-2004.
25. Masters GA, Xu R, Langer C. A phase II trial of carboplatin and gemcitabine with exisulind (IND # 65,056) in patients with advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Trial 1501 [abstract]. Proc Am Soc Clin Oncol 2004;23(suppl):7037.
26. Wang XF, Govindan R, Herndon JE, et al. A phase II study of carboplatin, etoposide and exisulind in patients with extensive stage small cell lung cancer: CALGB 30104 [abstract]. J Clin Oncol 2005;23(suppl):7161.
27. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-784.
28. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:785-794.
29. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
30. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotherapy in advanced non-small cell lung cancer [abstract]. J Clin Oncol 2004;22(suppl):7010.
31. Leighl NB, Paz-Ares L, Douillard JY, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 2005;23:2831-2839.
32. Edelman MJ, Smith R, Hausner P, et al. Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5774-5778.
33. Villalona-Calero MA, Ritch P, Figueroa JA, et al. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004;10:6086-6093.
34. Sandler AB, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.